PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE

Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.410
https://www.valueinhealthjournal.com/article/S1098-3015(19)32788-3/fulltext
Title : PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32788-3&doi=10.1016/j.jval.2019.09.410
First page :
Section Title :
Open access? : No
Section Order : 10338
Categories :
Tags :
Regions :
ViH Article Tags :